Details

Autor(en) / Beteiligte

• He, Gang, MD
• Holcroft, Christina A., PhD
• Beauchamp, Marie-Claude, PhD
• Yasmeen, Amber, PhD
• Ferenczy, Alex, MD
• Kendall-Dupont, Jennifer, BSc
• Mes-Masson, Anne-Marie, PhD
• Provencher, Diane, MD
• Gotlieb, Walter H., MD, PhD

Titel

Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours

Ist Teil von

• Journal of obstetrics and gynaecology Canada, 2012-06, Vol.34 (6), p.567-574

Ort / Verlag

Netherlands: Elsevier Inc

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Objective To investigate biomarkers and clinical parameters to distinguish ovarian cancers from benign ovarian tumours. Methods Serum biomarkers (CA 125, human epididymis protein 4 [HE 4], interleukin-18 [IL-18], leptin, macrophage migration inhibitory factor [MIF], fibroblast growth factor 2 [FGF-2], insulin-like growth factor, osteopontin, prolactin) and the risk of malignancy indexes I & II (RMI-I and RMI-II) scores were obtained prior to surgery in 52 patients with ovarian tumours (37 malignant and 15 benign). ROC curves were built for each individual marker, for logistic regression models using all markers, and for models combining both biomarkers and RMI scores. Results The model with nine biomarkers performed well (specificity 93%, sensitivity 84%) and was more reliable than the RMI-I or RMI-II alone. A regression model combining RMI-II and six of the biomarkers (CA 125, HE 4, IL-18, leptin, MIF, and FGF-2) allowed differentiation between the cancer and non-cancer cases in this pilot study Conclusion The regression models using biomarkers combined with clinical scoring systems warrant further investigation to improve triage of patients with ovarian tumours to enhance utilization of resources and optimize patient care.